SC 13D 1 net13dwang.txt NET FORCE SYSTEMS SCHEDULE 13D, LILY WANG SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D ------------ Under the Securities Exchange Act of 1934 (Amendment No.--)* Sinovac Biotech Ltd. -------------------- (Name of Issuer) Common Stock, par value $0.001 ------------------------------ (Title of Class of Securities) P8696W104 --------- (CUSIP Number) Michael T. Shannon, Esq. Devlin Jensen Barristers & Solicitors Suite 2550 - 555 W. Hastings Street Vancouver, British Columbia Canada V6B 4N5 (604) 684-2550 -------------- (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) September 24, 2003 ------------------ (Date of Event Which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13D to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. [ ] *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). Page 1 of 5 Pages CUSIP NO.: P8696W104 13D Page 2 of 5 Pages -------------------------------------------------------------------------------- (1) NAME OF REPORTING PERSON I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Lily Wang -------------------------------------------------------------------------------- (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ] (See Instructions) (b) [ ] -------------------------------------------------------------------------------- (3) SEC USE ONLY -------------------------------------------------------------------------------- (4) SOURCE OF FUNDS (See Intructions) OO (See Item 3) -------------------------------------------------------------------------------- (5) CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED [ ] PURSUANT TO ITEMS 2(d) OR 2(e) -------------------------------------------------------------------------------- (6) CITIZENSHIP OR PLACE OF ORGANIZATION United States -------------------------------------------------------------------------------- (7) SOLE VOTING POWER Number of Shares 10,000,000 Beneficially ----------------------------------------------------------------- Owned by (8) SHARED VOTING POWER Each Reporting 0 Person With ----------------------------------------------------------------- (9) SOLE DISPOSITIVE POWER 10,000,000 ----------------------------------------------------------------- (10) SHARED DISPOSITIVE POWER 0 -------------------------------------------------------------------------------- (11) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 10,000,000 -------------------------------------------------------------------------------- (12) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) [ ] -------------------------------------------------------------------------------- (13) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 36.9% -------------------------------------------------------------------------------- (14) TYPE OF REPORTING PERSON (See Instructions) IN -------------------------------------------------------------------------------- CUSIP NO.: P8696W104 13D Page 3 of 5 Pages Item 1. SECURITY AND ISSUER The class of equity securities to which this statement relates is common stock, $0.001 par value per share (the "Common Stock") of Sinovac Biotech Ltd., a corporation organized under the laws of the Country of Antigua (the "Issuer"). The address of the principal executive offices of the Issuer is Suite #10 - Epicurean, Woods Centre, P.O. Box W-645, St. John's, Antigua, West Indies. Item 2. IDENTITY AND BACKGROUND (a) - (c) Lily Wang's principal occupation is President of USA Xinyu Co. Ltd. and Chief Financial Officer of the Issuer. Ms. Wang's residential address is 300 Murchison Dr., Suite 202, Millbrae, California 94030. (d) - (f) During the last five years, Ms. Lily Wang has not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors). In addition, during the last five years, Ms. Lily Wang has not been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction; and therefore, is not subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. Ms. Lily Wang is citizen of the United States. Item 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION Ms. Lily Wang was the beneficial owner of 68,136,000 shares of Sinovac Biotech Co., Ltd., a company organized under the laws of the People's Republic of China, which represented not less than 51% ownership in Sinovac Biotech Co., Ltd. Pursuant to Share Purchase Agreement dated September 24, 2003, between Ms. Lily Wang and the Issuer, the Issuer acquired Ms. Wang's 68,136,000 shares of Sinovac Biotech Co., Ltd. in consideration for 10,000,000 newly issued shares of Common Stock of the Issuer, at a stated value of $0.60 per share, constituting approximately 37% of the Issuer's outstanding capital stock after such issuance on a fully diluted basis. Item 4. PURPOSE OF TRANSACTION Ms. Lily Wang is currently holding the shares for investment purposes. Ms. Lily Wang has no plans or proposals that relate to or that would result in any of the actions specified in clauses (a) through (j) of Item 4 of Schedule 13D. However, immediately prior to the Issuer entering into the Share Purchase agreement with Ms. Lily Wang, dated September 24, 2003, the Issuer appointed Mr. Wei Dong Yin, Ms. Lily Wang and Mr. He Ping Wang as directors of the Issuer. In addition, Mr. Terry Bowering, director, President, Chief Executive Officer and Chief Financial Officer, Mr. Trevor Bowering, director, Mr. Dwight Lewis, CUSIP NO.: P8696W104 13D Page 4 of 5 Pages director and Mr. Derek Ferguson, director, each tendered their resignation to the Board and the Board of Directors accepted each resignation. Upon the Board's acceptance of Mr. Terry Bowering's resignation, Mr. Yin was appointed President and Chief Executive Officer and Ms. Lily Wang was appointed Chief Financial Officer. Item 5. INTEREST IN SECURITIES OF THE ISSUER (a) Ms. Lily Wang currently owns 10,000,000 shares of Common Stock of the Issuer which represents approximately 37% of the outstanding Common Stock of the Issuer. This percentage is based on 27,066,033 shares of Common Stock issued and outstanding. (b) Ms. Lily Wang has the sole power to vote or to direct the vote and the sole power to dispose or direct the disposition of 10,000,0000 shares of Common Stock. (c) Except as otherwise described herein, and to the knowledge of Ms. Lily Wang, Ms. Lily Wang has not affected any transaction in the Common Stock during the past sixty (60) days. (d) Except as otherwise described herein, and to the knowledge of Ms. Lily Wang, no other person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from sale of, the Common Stock owned by Ms. Lily Wang. (e) It is inapplicable for the purpose herein to state the date on which Ms. Lily Wang ceased to be an owner of more than five percent (5%) of the Common Stock. Item 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO THE SECURITIES OF THE ISSUER Except as otherwise described herein, there are no contracts, arrangements, understandings or relationships (legal or otherwise) between Ms. Lily Wang and any other person with respect to the voting or disposition of the shares of Common Stock beneficially owned by Ms. Lily Wang. Item 7. MATERIAL TO BE FILED AS EXHIBITS Not Applicable as there are no exhibits to be filed with this Schedule 13D. CUSIP NO.: P8696W104 13D Page 5 of 5 Pages SIGNATURE --------- After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: October 31, 2003 /s/ Lily Wang ----------------------------- Lily Wang